"Bradykinin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter.
| Descriptor ID |
D001920
|
| MeSH Number(s) |
D12.644.276.812.169 D12.644.400.090 D12.644.456.193 D12.776.467.812.169 D12.776.631.650.090 D23.469.050.375.110 D23.529.812.169
|
| Concept/Terms |
Bradykinin- Bradykinin
- Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg
- Arg Pro Pro Gly Phe Ser Pro Phe Arg
|
Below are MeSH descriptors whose meaning is more general than "Bradykinin".
Below are MeSH descriptors whose meaning is more specific than "Bradykinin".
This graph shows the total number of publications written about "Bradykinin" by people in this website by year, and whether "Bradykinin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1995 | 1 | 2 | 3 |
| 1996 | 4 | 1 | 5 |
| 1997 | 2 | 3 | 5 |
| 1998 | 2 | 2 | 4 |
| 1999 | 1 | 3 | 4 |
| 2000 | 2 | 2 | 4 |
| 2001 | 2 | 2 | 4 |
| 2002 | 5 | 0 | 5 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 0 | 2 |
| 2005 | 2 | 2 | 4 |
| 2006 | 1 | 3 | 4 |
| 2007 | 1 | 2 | 3 |
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 2 | 2 |
| 2010 | 8 | 1 | 9 |
| 2011 | 1 | 0 | 1 |
| 2013 | 4 | 1 | 5 |
| 2014 | 5 | 1 | 6 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2020 | 3 | 1 | 4 |
| 2021 | 2 | 3 | 5 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bradykinin" by people in Profiles.
-
Bradykinin formation by mutant plasminogen. Blood. 2022 05 05; 139(18):2732-2733.
-
Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade. J Allergy Clin Immunol Pract. 2022 03; 10(3):716-722.
-
gC1qR Antibody Can Modulate Endothelial Cell Permeability in Angioedema. Inflammation. 2022 Feb; 45(1):116-128.
-
Identification of Human Kinin-Forming Enzyme Inhibitors from Medicinal Herbs. Molecules. 2021 Jul 07; 26(14).
-
Analysis of cold activation of the contact system in hereditary angioedema with normal C1 inhibitor. Mol Immunol. 2021 08; 136:150-160.
-
Blood Clotting and the Pathogenesis of Types I and II Hereditary Angioedema. Clin Rev Allergy Immunol. 2021 Jun; 60(3):348-356.
-
Hereditary angioedema: Investigational therapies and future research. Allergy Asthma Proc. 2020 11 01; 41(Suppl 1):S51-S54.
-
Pathways for bradykinin formation and interrelationship with complement as a cause of edematous lung in COVID-19 patients. J Allergy Clin Immunol. 2021 Feb; 147(2):507-509.
-
Protease activity in single-chain prekallikrein. Blood. 2020 02 20; 135(8):558-567.
-
Preventing anaphylaxis fatalities: Should we target bradykinin? J Allergy Clin Immunol. 2020 05; 145(5):1365-1366.